Esperante invests EUR 500,000 to EUR 5,000,000 in syndication with other investors with an exit objective of sale or other liquidity outcomes within a period of 3 years. Our current focus for new investments is on pharmaceutical companies entering Phase 2b to Phase 3 clinical development.
Our approach
Endocrinology
Fertility
Gastroenterology
Gynaecology
Hepatology
Infectious disease
Oncology
Ophthalmology
Otology (hearing)
Urology / uro-oncology
Women’s health